AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19

This is a Phase I, first time in human, randomised, double-blind, placebo-controlled, and dose escalation study. The study will comprise of: 1. A Screening Period of up to 27 days (Day -28 through Day -2); 2. A Treatment Period during which participants will be resident at the Clinical Unit from Day -1, 1 day before Investigational Medicinal Product (IMP) administration (on Day 1) until at least 24 hours after IMP administration, will be discharged on Day 2 after all safety evaluations have been completed, and 3. A Follow up Period lasting 360 days (through to Day 361) after the IMP dose. The study will be conducted at a single study centre in United Kingdom.